18F-FET PET在儿童中枢神经系统肿瘤中的诊断准确性与临床影响
该前瞻性队列纳入97例已知或疑似儿童中枢神经系统肿瘤患者,共完成169次18F-FET PET扫描。在MRI基础上加做18F-FET PET使8%的扫描临床管理发生变化,在MRI难以决策的扫描中达33%;对治疗过的病灶,联合PET提高了特异性(1.00 vs 0.48)和准确性(0.91 vs 0.81)。
要点
- 在MRI基础上加做18F-FET PET可帮助区分肿瘤与非肿瘤病变。
- 对MRI难以决策的病例,加做PET的临床管理影响可达33%。
- 治疗过的病灶中,加做PET提高特异性至1.00、准确性至0.91。
核心结论
- 在MRI基础上加做18F-FET PET有助于儿童中枢神经系统肿瘤患者区分肿瘤与非肿瘤病变。
研究设计与样本
- 前瞻性连续纳入97例已知或疑似儿童中枢神经系统肿瘤患者,共完成169次18F-FET PET扫描。
- 扫描时机包括初诊时、治疗前或治疗后、以及复发时。
主要发现
- 加做18F-FET PET影响8%[95%CI:4%-13%]的全部扫描(n=151)的临床管理。
- 在因单独MRI难以决策而临床指示的扫描中,影响33%[95%CI:17%-53%](n=30)的临床管理。
- 以病理或随访为参考标准,在83个治疗过的病灶中,加做PET提高特异性(1.00[0.82-1.00] vs 0.48[0.30-0.70],P=.0001)和准确性(0.91[95%CI:0.87-0.96] vs 0.81[95%CI:0.75-0.89],P=.04)。
- 在58个未治疗病灶中,加做PET提高准确性(0.96[95%CI:0.91-1.00] vs 0.90[95%CI:0.82-0.92],P<.001)。
- 在15例患者亚组中,18F-FET摄取与基因组增殖指数呈正相关。
临床怎么用
- 对于儿童中枢神经系统肿瘤,当MRI难以区分肿瘤与治疗相关改变时,可考虑加做18F-FET PET辅助决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Central nervous system (CNS) tumors cause the highest death rates among childhood cancers, and survivors frequently have severe late effects. Magnetic resonance imaging (MRI) is the imaging modality of choice, but its specificity can be challenged by treatment-induced signal changes. In adults, O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) PET can assist in interpreting MRI findings. We assessed the clinical impact and diagnostic accuracy of adding [18F]FET PET to MRI in children with CNS tumors. METHODS: A total of 169 [18F]FET PET scans were performed in 97 prospectively and consecutively included patients with known or suspected childhood CNS tumors. Scans were performed at primary diagnosis, before or after treatment, or at relapse. RESULTS: Adding [18F]FET PET to MRI impacted clinical management in 8% [95% confidence interval (CI): 4%-13%] of all scans (n = 151) and in 33% [CI: 17%-53%] of scans deemed clinically indicated due to difficult decision making on MRI alone (n = 30). Using pathology or follow-up as reference standard, the addition of [18F]FET PET increased specificity (1.00 [0.82-1.00] vs 0.48 [0.30-0.70], P = .0001) and accuracy (0.91 [CI: 0.87-0.96] vs 0.81 [CI: 0.75-0.89], P = .04) in 83 treated lesions and accuracy in 58 untreated lesions (0.96 [CI: 0.91-1.00] vs 0.90 [CI: 0.82-0.92], P < .001). Further, in a subset of patients (n = 15) [18F]FET uptake correlated positively with genomic proliferation index. CONCLUSIONS: The addition of [18F]FET PET to MRI helped discriminate tumor from non-tumor lesions in the largest consecutive cohort of pediatric CNS tumor patients presented to date.
引用
- Marner L, Lundemann M, Sehested A, et al. Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors. Neuro Oncol. 2021. PMID: 33864083. doi:10.1093/neuonc/noab096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。